Interleukin 10 inhibits vascular permeability factor release by peripheral blood mononuclear cells in patients with lipoid nephrosis.
The effect of recombinant human interleukin 10 (IL-10) on the in vitro secretion of vascular permeability factor (VPF) of peripheral blood mononuclear cells (PBMC) was evaluated in patients with lipoid nephrosis (LN). Significantly increased spontaneous and concanavalin A (ConA) stimulated secretion of VPF was detected in PBMC cultures of LN patients with the nephrotic syndrome as compared with those of normal controls. In the present study, IL-10 inhibited the ConA-stimulated VPF secretion of PBMC in LN. A significant inhibitory effect of IL-10 was observed in cultures of PBMC from LN and IgA nephropathy patients as well as from normal persons. When both ConA and anti-IL-10 antibody were added together to the PBMC, a further increase in ConA-stimulated secretion of VPF occurred. These data suggest that IL-10 is a powerful inhibitor of the secretion of VPF in LN patients.
Matsumoto
K
K
2nd Department of Internal Medicine, Nihon University School of Medicine, Tokyo, Japan.
D000293:Adolescent; D000328:Adult; D016228:Endothelial Growth Factors / Q000378:metabolism*; D005260:Female; D005922:Glomerulonephritis, IGA / Q000097:blood / Q000188:drug therapy; D005938:Glucocorticoids / Q000627:therapeutic use; D006801:Humans; D016753:Interleukin-10 / Q000627:therapeutic use*; D007963:Leukocytes, Mononuclear / Q000187:drug effects* / Q000378:metabolism*; D008222:Lymphokines / Q000378:metabolism*; D008297:Male; D008875:Middle Aged; D009402:Nephrosis, Lipoid / Q000097:blood* / Q000188:drug therapy*; D011239:Prednisolone / Q000627:therapeutic use; D042461:Vascular Endothelial Growth Factor A; D042442:Vascular Endothelial Growth Factors
D016228:Endothelial Growth Factors; D005938:Glucocorticoids; D008222:Lymphokines; D042461:Vascular Endothelial Growth Factor A; D042442:Vascular Endothelial Growth Factors; D016753:Interleukin-10; D011239:Prednisolone